| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Imaging, Diagnosis, Prognosis |
Authors' Affiliations: 1 Cleveland Clinic Foundation, Cleveland, Ohio; 2 M.D. Anderson Cancer Center, Houston, Texas; 3 Washington University, St. Louis, Missouri; 4 University of Arizona, Tucson, Arizona; 5 Immunicon Corp., Huntingdon Valley, Pennsylvania; and 6 University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Requests for reprints: G. Thomas Budd, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195. Phone: 216-444-6480; Fax: 216-445-2369; E-mail: buddg{at}ccf.org.
Purpose: The presence of 
5 circulating tumor cells (CTC) in 7.5 mL blood from patients with measurable metastatic breast cancer before and/or after initiation of therapy is associated with shorter progression-free and overall survival. In this report, we compared the use of CTCs to radiology for prediction of overall survival.
Experimental Design: One hundred thirty-eight metastatic breast cancer patients had imaging studies done before and a median of 10 weeks after the initiation of therapy. All scans were centrally reviewed by two independent radiologists using WHO criteria to determine radiologic response. CTC counts were determined 
4 weeks after initiation of therapy. Specimens were analyzed at one of seven laboratories and reviewed by a central laboratory.
Results: Interreader variability for radiologic responses and CTC counts were 15.2% and 0.7%, respectively. The median overall survival of 13 (9%) patients with radiologic nonprogression and 5 CTCs was significantly shorter than that of the 83 (60%) patients with radiologic nonprogression and <5 CTCs (15.3 versus 26.9 months; P = 0.0389). The median overall survival of the 20 (14%) patients with radiologic progression and <5 CTCs was significantly longer than the 22 (16%) patients with 5 CTCs that showed progression by radiology (19.9 versus 6.4 months; P = 0.0039).
Conclusions: Assessment of CTCs is an earlier, more reproducible indication of disease status than current imaging methods. CTCs may be a superior surrogate end point, as they are highly reproducible and correlate better with overall survival than do changes determined by traditional radiology.
Commentary
Clin. Cancer Res. 2006 12: 6321-6322.
This article has been cited by other articles:
|
|
 |
|
  U. De Giorgi, V. Valero, E. Rohren, S. Dawood, N. T. Ueno, M. C. Miller, G. V. Doyle, S. Jackson, E. Andreopoulou, B. C. Handy, et al. Circulating Tumor Cells and [18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer J. Clin. Oncol., July 10, 2009; 27(20): 3303 - 3311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lu, P. S. Steeg, J. E. Price, S. Krishnamurthy, S. A. Mani, J. Reuben, M. Cristofanilli, G. Dontu, L. Bidaut, V. Valero, et al. Breast Cancer Metastasis: Challenges and Opportunities Cancer Res., June 15, 2009; 69(12): 4951 - 4953. [Full Text] [PDF]
|
|
|
|
 |
|
 O. B. Goodman Jr., L. M. Fink, J. T. Symanowski, B. Wong, B. Grobaski, D. Pomerantz, Y. Ma, D. C. Ward, and N. J. Vogelzang Circulating Tumor Cells in Patients with Castration-Resistant Prostate Cancer Baseline Values and Correlation with Prognostic Factors Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1904 - 1913. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Helo, A. M. Cronin, D. C. Danila, S. Wenske, R. Gonzalez-Espinoza, A. Anand, M. Koscuiszka, R.-M. Vaananen, K. Pettersson, F. K.-H. Chun, et al. Circulating Prostate Tumor Cells Detected by Reverse Transcription-PCR in Men with Localized or Castration-Refractory Prostate Cancer: Concordance with CellSearch Assay and Association with Bone Metastases and with Survival Clin. Chem., April 1, 2009; 55(4): 765 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Talasaz, A. A. Powell, D. E. Huber, J. G. Berbee, K.-H. Roh, W. Yu, W. Xiao, M. M. Davis, R. F. Pease, M. N. Mindrinos, et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device PNAS, March 10, 2009; 106(10): 3970 - 3975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Gallagher, M. I. Milowsky, N. Ishill, A. Trout, M. G. Boyle, J. Riches, M. Fleisher, and D. F. Bajorin Detection of circulating tumor cells in patients with urothelial cancer Ann. Onc., February 1, 2009; 20(2): 305 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Olmos, H.-T. Arkenau, J. E. Ang, I. Ledaki, G. Attard, C. P. Carden, A. H. M. Reid, R. A'Hern, P. C. Fong, N. B. Oomen, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience Ann. Onc., January 1, 2009; 20(1): 27 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hiraiwa, H. Takeuchi, H. Hasegawa, Y. Saikawa, K. Suda, T. Ando, K. Kumagai, T. Irino, T. Yoshikawa, S. Matsuda, et al. Clinical Significance of Circulating Tumor Cells in Blood from Patients with Gastrointestinal Cancers Ann. Surg. Oncol., November 1, 2008; 15(11): 3092 - 3100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Pierga, F.-C. Bidard, C. Mathiot, E. Brain, S. Delaloge, S. Giachetti, P. de Cremoux, R. Salmon, A. Vincent-Salomon, and M. Marty Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial Clin. Cancer Res., November 1, 2008; 14(21): 7004 - 7010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. de Bono, H. I. Scher, R. B. Montgomery, C. Parker, M. C. Miller, H. Tissing, G. V. Doyle, L. W.W.M. Terstappen, K. J. Pienta, and D. Raghavan Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer Clin. Cancer Res., October 1, 2008; 14(19): 6302 - 6309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Alix-Panabieres, S. Riethdorf, and K. Pantel Circulating Tumor Cells and Bone Marrow Micrometastasis Clin. Cancer Res., August 15, 2008; 14(16): 5013 - 5021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Eliane, M. Repollet, K. E. Luker, M. Brown, J. M. Rae, G. Dontu, A. F. Schott, M. Wicha, G. V. Doyle, D. F. Hayes, et al. Monitoring Serial Changes in Circulating Human Breast Cancer Cells in Murine Xenograft Models Cancer Res., July 15, 2008; 68(14): 5529 - 5532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Hayes and J. Smerage Is There a Role for Circulating Tumor Cells in the Management of Breast Cancer? Clin. Cancer Res., June 15, 2008; 14(12): 3646 - 3650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. O. Abdalla, P. Kokhaei, L. Hansson, H. Mellstedt, and A. Osterborg Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC) Ann. Onc., June 1, 2008; 19(6): 1172 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Nole, E. Munzone, L. Zorzino, I. Minchella, M. Salvatici, E. Botteri, M. Medici, E. Verri, L. Adamoli, N. Rotmensz, et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications Ann. Onc., May 1, 2008; 19(5): 891 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Sargent and D. F. Hayes Assessing the Measure of a New Drug: Is Survival the Only Thing That Matters? J. Clin. Oncol., April 20, 2008; 26(12): 1922 - 1923. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Pantel, C. Alix-Panabieres, and S. Riethdorf Circulating Tumor Cells: Detection and Clinical Relevance Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 603 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-C. Bidard, A. Vincent-Salomon, B. Sigal-Zafrani, V. Dieras, C. Mathiot, L. Mignot, J.-P. Thiery, X. Sastre-Garau, and J.-Y. Pierga Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells Ann. Onc., March 1, 2008; 19(3): 496 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Said, A. Agarwal, M. Zborowski, S. Grunewald, H.-J. Glander, and U. Paasch Utility of Magnetic Cell Separation as a Molecular Sperm Preparation Technique J Androl, March 1, 2008; 29(2): 134 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Carden, D. Olmos, and J. S. de Bono Validated and Qualified Biomarkers Are Critical to Optimizing Anticancer Drug Development: Potential Roles for the Study of Circulating Tumor Cells ASCO Educational Book, January 1, 2008; 2008(1): 166 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Danila, G. Heller, G. A. Gignac, R. Gonzalez-Espinoza, A. Anand, E. Tanaka, H. Lilja, L. Schwartz, S. Larson, M. Fleisher, et al. Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer Clin. Cancer Res., December 1, 2007; 13(23): 7053 - 7058. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5287 - 5312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Sledge Jr. Circulating tumor cells in breast cancer: blood will tell. Clin. Cancer Res., November 1, 2006; 12(21): 6321 - 6322. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
